Liu, Hongzhong
Zhao, Qian
Yuan, Yuping
Wang, Zhenlei
Wang, Teng
Tian, Wei
Zhong, Wen
Jiang, Ji
Chen, Shuai
Kong, Kai
Jin, Chunyan
Hu, Pei
Clinical trials referenced in this document:
Documents that mention this clinical trial
First-in-Human Safety, Tolerability, and Pharmacokinetics of Single-Dose Kukoamine B Mesylate in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase I Study
https://doi.org/10.1007/s40121-024-00921-6
Funding for this research was provided by:
Tianjin Chasesun Pharmaceutical Co., Ltd, China
National High Level Hospital Clinical Research Funding (2022-PUMCH-B-118, 2022-PUMCH-A-144, 2022-PUMCH-B-033)
Jinqiao Project of Beijing Association of Science and Technology (ZZ19005)
Drug Development and Application of Chinese Pharmacological Society (2019DL001)
Article History
Received: 16 November 2023
Accepted: 10 January 2024
First Online: 30 January 2024
Declarations
:
: Hongzhong Liu, Qian Zhao, Yuping Yuan, Zhenlei Wang, Teng Wang, Wei Tian, Wen Zhong, Ji Jiang, and Pei Hu declare no conflicts of interest. Shuai Chen, Kai Kong, and Chunyan Jin are full-time employees of Tianjin Chasesun Pharmaceutical Co., Ltd.
: The study was performed in accordance with the International Conference on Harmonization Good Clinical Practice guidelines and ethical principles that have their origin in the Declaration of Helsinki of 1964 and its later amendments. This study was approved by the Ethics Review Board of Peking Union Medical College Hospital (approved no. 2014L01029). All participants provided written informed consent before enrollment.